Wordt geladen...
PD-1/PD-L1 inhibitors
Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. Nivolumab...
Bewaard in:
| Gepubliceerd in: | Curr Opin Pharmacol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516625/ https://ncbi.nlm.nih.gov/pubmed/26047524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2015.05.011 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|